BRAF and melanoma: With this in mind, and to improve our understanding of the complexity of MITF‐high melanomas in the context of MAPK inhibitor resistance, we set out to analyse the dynamics of individual MITF‐expressing subpopulations during treatment with BRAF inhibitor.